CIPLA vs VALIANTLAB: Stock Comparison

Cipla Ltd vs Valiant Laboratories Limited

Live data: 22 July 2026, 2:34 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher ROE, a higher dividend yield and lower leverage, while Valiant Laboratories Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Valiant Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 7 of 13 scored metrics and VALIANTLAB on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹332 Cr
P/E Ratio
VALIANTLAB has a lower P/E
-101.88x vs 29.83x
P/B Ratio
VALIANTLAB has a lower P/B
1.07x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹-0.05
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0%
Revenue Growth (TTM YoY)
VALIANTLAB has faster revenue growth
0% vs -2.1%
EPS Growth (TTM YoY)
VALIANTLAB has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
VALIANTLAB has stronger quarterly sales growth
148% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAVALIANTLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAVALIANTLAB
Live Price₹1,410.9₹81.65
Day Change-1.51%2.55%
Volume12.88 L87,489
52-Week High₹1,673₹100.98
52-Week Low₹1,165.7₹49.51
Distance from 52W High-15.67%-19.14%

Valuation

MetricCIPLAVALIANTLAB
Market Cap₹1.14 L Cr₹332 Cr
P/E Ratio29.83x-101.88x
P/B Ratio3.36x1.07x
EPS₹48.01₹-0.05
Book Value₹426.25₹50.08
Dividend Yield0.9%0%

Growth

MetricCIPLAVALIANTLAB
Revenue Growth (TTM YoY)-2.1%0%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth-2.8%148%
Qtr Profit Growth-54.6%457%

Profitability & Leverage

MetricCIPLAVALIANTLAB
ROE11.6%-1.05%
ROCE15.5%-0.95%
Net Margin13.96%-1.38%
Operating Margin20.9%1.12%
Debt to Equity0.02x0.14x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAVALIANTLAB
Promoter Holding9.17%74.94%
FII Holding22.56% 1.37 pp0% 0.2 pp
DII Holding31.97% 1.25 pp0%
Public Holding16.25% 0.12 pp25.06% 0.2 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Valiant Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.